Start Date
28-10-2020 11:29 AM
End Date
October 2020
Description
HIV has infected approximately 37 million people worldwide and results in over 1 million deaths annually. A key component of the HIV life cycle is the enzyme HIV-1 protease, which is involved in cutting newly made protein components of the HIV virion. Our research focused on how can molecular models be used to simulate the binding of various HIV-1 prtease inhibitors including Darunavir, Ritonavir, and a novel combination of these two named "Sharkavir".
Poster
2-2019-2020 Model Description Sheet Nova11.14.19.pdf (327 kB)
Handout
Included in
Development of “Sharkavir”: A New Hypothetical Inhibitor for HIV-1 Protease
HIV has infected approximately 37 million people worldwide and results in over 1 million deaths annually. A key component of the HIV life cycle is the enzyme HIV-1 protease, which is involved in cutting newly made protein components of the HIV virion. Our research focused on how can molecular models be used to simulate the binding of various HIV-1 prtease inhibitors including Darunavir, Ritonavir, and a novel combination of these two named "Sharkavir".